2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-13736A
    Quinagolide hydrochloride 94424-50-7 99.55%
    Quinagolide hydrochloride (CV205-502 hydrochloride) is a selective and orally active dopamine D2 receptor agonist. Quinagolide hydrochloride is an inhibitor of prolactin. Quinagolide hydrochloride down-regulates AKT levels and its phosphorylation. Quinagolide hydrochloride shows antitumor effects, it can be used for the research of cancer.
    Quinagolide hydrochloride
  • HY-139559
    Vornorexant 1517965-94-4 98.41%
    Vornorexant (ORN-0829; TS-142) is a potent dual OX1R and OX2R antagonist with IC50 values of 1.05 nM and 1.27 nM, respectively. Vornorexant exhibits potent sleep-promoting effects in vivo and can be used for insomnia research research.
    Vornorexant
  • HY-148772
    PTC258 2476724-74-8 99.84%
    PTC258 is a specific and orally active splicing modulator of Elongator complex protein 1 gene (ELP1). PTC258 increases the expression of ELP1 in vitro and in vivo. PTC258 is well tolerated in mouse model.
    PTC258
  • HY-148907
    CS640 2388506-83-8 99.48%
    CS640 (Compound 19) is a chemical probe and a calmodulin-dependent kinase inhibitor. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, MEK5, RIPK4, mLK3 and PIP5K1, with IC50 values of 8, 3, 1, 1, 25 nM, 5.69, 2.75 and 11.2 μM, respectively. CS640 blocks Aβ-induced hyperphosphorylation of tau protein at the Thr181 site, but fails to protect primary mouse cortical neurons from Aβ-induced toxic damage. CS640 is applicable to research related to Alzheimer's disease.
    CS640
  • HY-155659
    4A7C-301 99.86%
    4A7C-301 is a Nurr1 agonist with robust neuroprotective effects in vitro. 4A7C-301 significantly ameliorates neuropathological abnormalities and improves motor and olfactory dysfunctions in AAV2-mediated α-synuclein-overexpressing male mouse models. 4A7C-301 can be used for the research of Parkinson’s disease.
    4A7C-301
  • HY-157802
    LTGO-33 2834106-06-6 98.83%
    LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research.
    LTGO-33
  • HY-158155
    CVN293 2815296-08-1 99.91%
    CVN293 is a selective and brain permeable potassium ion (K+) channel KCNK13 inhibtor with IC50s of 41 nM and 28 nM for hKCNK13 and mKCNK13, respectively. CVN293 potently inhibits the NLRP3-inflammasome mediated production of the proinflammatory cytokine IL-1β in microglia.
    CVN293
  • HY-171579
    RS47 301655-16-3 98.0%
    RS47 is a selective RelB inhibitor with a Kd value of 1.1 μM. RS47 also acts as an inhibitor of HCV replication. RS47 can block the non-canonical NF-κB signaling pathway without affecting the canonical pathway. RS47 exerts anti-tumor effects of inhibiting proliferation and promoting apoptosis on colorectal cancer, B-cell lymphoma and other related tumors both in vitro and in vivo by disrupting the binding of RelB to target DNA. RS47 can be used for the research of tumors and infectious diseases.
    RS47
  • HY-18618A
    SB-612111 hydrochloride 99.64%
    SB-612111 hydrochloride hydrochloride is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). SB-612111 hydrochloride exhibits selectivity for μ-,?κ- and?δ-receptors with Ki values of?57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 hydrochloride effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model.
    SB-612111 hydrochloride
  • HY-19627A
    Naldemedine tosylate 1345728-04-2
    Naldemedine (S-297995) tosylate is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine tosylate shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine tosylate is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
    Naldemedine tosylate
  • HY-N6785A
    Okadaic acid sodium 209266-80-8 99.90%
    Okadaic acid sodium, a marine toxin, is an inhibitor of protein phosphatases (PP). Okadaic acid (sodium) has a significantly higher affinity for PP2A (IC50=0.1-0.3 nM), and inhibits PP1 (IC50=15-50 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), but does not inhibit PP2C. Okadaic acid sodium increases of phosphorylation of a number of proteins by inhibiting PP, and acts a tumor promoter. Okadaic acid sodium induces tau phosphorylation.
    Okadaic acid sodium
  • HY-P1205A
    MCH(human, mouse, rat) TFA 99.09%
    MCH (human, mouse, rat) TFA is a cyclic neuropeptide mainly synthesized by neurons in the lateral hypothalamic area. MCH (human, mouse, rat) TFA also serves as an endogenous ligand for the melanin-concentrating hormone receptor (MHC receptor), with a binding IC50 of 0.3 nM and 1.5 nM for human MCH-1R and MCH-2R, respectively; its functional EC50 values are 3.9 nM and 88.7 nM. MCH (human, mouse, rat) TFA acts not only as an orexigenic signal but also as a key integrating and regulatory hormone for energy homeostasis and sleep-wake cycles. MCH (human, mouse, rat) TFA can be used in studies related to obesity, sleep disorders, and other associated conditions.
    MCH(human, mouse, rat) TFA
  • HY-101299B
    Dihydrexidine hydrochloride 137417-08-4 98.89%
    Dihydrexidine hydrochloride (DAR-0100 hydrochloride) is a high potent, selective and full efficacy D1-like dopamine receptor (D1/D5) agonist, with an IC50 of 10 nM for D1 receptor. Dihydrexidine hydrochloride exhibits potent antiparkinsonian activity. Dihydrexidine hydrochloride can stimulate YAP phosphorylation.
    Dihydrexidine hydrochloride
  • HY-108577A
    XE991 122955-42-4 99.69%
    XE 991 dihydrochloride, a Kv7 (KCNQ) channels blocker, potently inhibits Kv7.1 (KCNQ1), Kv7.2 (KCNQ2), Kv7.2 + Kv7.3 (KCNQ3) channel, and M-current with IC50s of 0.75 μM, 0.71 μM, 0.6 μM, and 0.98 μM, respectively.
    XE991
  • HY-113468A
    3-O-Methyldopa 300-48-1 99.55%
    3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA (HY-N0304) that can cross the blood-brain barrier (BBB). 3-O-Methyldopa inhibits the astrocyte-mediated protective effect of L-DOPA (HY-N0304) on dopaminergic neurons. In addition, 3-O-Methyldopa has certain antidepressant and neuroprotective activities. 3-O-Methyldopa can be used in the research of nervous system diseases such as depression and Parkinson's disease.
    3-O-Methyldopa
  • HY-14608S8
    L-Glutamic acid-d3 203805-84-9 99.26%
    L-Glutamic acid-d3 is the deuterium labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-d3
  • HY-B0451AR
    Dopamine hydrochloride (Standard) 62-31-7 99.75%
    Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body. Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis.
    Dopamine hydrochloride (Standard)
  • HY-P991045
    Donanemab (Mouse IgG2a) 99.9%
    Donanemab (Mouse IgG2a) (mE8-IgG2a) is a mouse-derived IgG2 monoclonal antibody used in the research of Alzheimer's disease.
    Donanemab (Mouse IgG2a)
  • HY-W002112
    (±)-Nornicotine 5746-86-1
    (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia.
    (±)-Nornicotine
  • HY-W012906
    L-Allylglycine 16338-48-0 ≥98.0%
    L-Allylglycine (L-2-Allylglycine) is an amino acid derivative. L-Allylglycine is an inhibitor for glutamate decarboxylase (GAD) that reduces the GABA biosynthesis in the brain. L-Allylglycine exhibits convulsant activity.
    L-Allylglycine
Cat. No. Product Name / Synonyms Application Reactivity